-

Zoetis to Host Webcast and Conference Call on Third Quarter 2021 Financial Results

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 4, 2021. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2021 financial results and respond to questions from financial analysts during the call.

Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on Nov. 4, 2021.

About Zoetis

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After nearly 70 years innovating ways to predict, prevent, detect, and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide - from livestock farmers to veterinarians and pet owners. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics, and technologies make a difference in over 100 countries. In 2020, Zoetis generated revenue of $6.7 billion with ~11,300 employees. For more, visit www.zoetis.com.

ZTS-COR
ZTS-IR

Contacts

Media:
Bill Price
1-973-443-2742 (o)
william.price@zoetis.com

Kristen Seely
1-973-443-2777 (o)
kristen.seely@zoetis.com

Investors:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com

Keith Gaub
1-973-822-7154 (o)
keith.gaub@zoetis.com

Zoetis Inc.

NYSE:ZTS

Release Summary
Zoetis Inc. will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 4, 2021.
Release Versions
$Cashtags

Contacts

Media:
Bill Price
1-973-443-2742 (o)
william.price@zoetis.com

Kristen Seely
1-973-443-2777 (o)
kristen.seely@zoetis.com

Investors:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com

Keith Gaub
1-973-822-7154 (o)
keith.gaub@zoetis.com

More News From Zoetis Inc.

Zoetis Announces Second Quarter 2026 Results

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the second quarter of 2026. The company reported revenue of $2.5 billion for the second quarter of 2026, flat compared with the second quarter of 2025, decreasing 1% on an organic operational1 basis. Net income for the second quarter of 2026 was $691 million, or $1.65 per diluted share, decreasing 5% and growing 1%, respectively, on a reported basis. Adj...

Zoetis Appoints Jay Saccaro as Chief Financial Officer and Chief Operating Officer

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced the appointment of James (Jay) Saccaro as Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026. In this newly created role, Mr. Saccaro will lead Zoetis’ global finance function, shaping capital allocation, financial strategy, reporting and controls, and investor engagement and oversee Global Manufacturing and Supply to drive operational execution and performance. With...

Zoetis Launches Portela® (relfovetmab) in Canada and the European Union

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced the commercial launch of Portela® (relfovetmab) in Canada and the European Union (EU) member states. Portela is the first long-acting anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy for cats, designed to alleviate pain associated with osteoarthritis (OA) for up to three months with a single subcutaneous injection. Backed by nearly a decade of science and research, Portela demonstrated effectiveness in al...
Back to Newsroom